Revenue for the year ended December 31, 2023, was $563.6 million compared to $502.0 million for the same period in 2022. The increase was driven by significant growth in the Government segment as a result of the Company’s PCC community and continued strong customer demand across the Company’s HFS – South segment.
Net income was $173.7 million for the year ended December 31, 2023, compared to $73.9 million for the same period in 2022, a 135% increase.
Adjusted EBITDA was $344.2 million for the year ended December 31, 2023, compared to $264.7 million for the same period in 2022, a 30% increase.
Fourth Quarter Summary Highlights
| | | | | | | |
For the Three Months Ended ($ in '000s, except per share amounts) - (unaudited) | | December 31, 2023 | | December 31, 2022 | |
Revenue | | $ | 126,220 | | $ | 152,438 | |
Net income | | $ | 37,843 | | $ | 31,572 | |
Income per share – basic | | $ | 0.37 | | $ | 0.32 | |
Income per share – diluted | | $ | 0.29 | | $ | 0.31 | |
Adjusted EBITDA(1) | | $ | 67,659 | | $ | 90,825 | |
Average utilized beds | | | 13,981 | | | 14,207 | |
Utilization | | | 87 | % | | 90 | % |
Revenue for the three months ended December 31, 2023, was $126.2 million compared to $152.4 million for the same period in 2022. The decrease was primarily driven by lower non-cash, nonrecurring, infrastructure enhancement revenue associated with the Company’s PCC community, which was fully amortized as of November 2023.
Net income was $37.8 million for the three months ended December 31, 2023, compared to $31.6 million for the same period in 2022, driven by the change in fair value of warrant liabilities, lower interest expense, and lower income tax expense, partially offset by lower operating income led by the decrease in revenue explained above.
Adjusted EBITDA was $67.7 million for the three months ended December 31, 2023, compared to $90.8 million for the same period in 2022, the decrease was primarily driven by lower non-cash, nonrecurring, infrastructure enhancement revenue associated with the Company’s PCC community, which was fully amortized as of November 2023.
Capital Management
The Company had approximately $65.6 million of capital expenditures for the year ended December 31, 2023, including approximately $31.4 million of select asset acquisitions and associated asset enhancements. Capital expenditures were predominantly focused on aligning portfolio capabilities and capacity with strong customer demand and enhancing certain assets in support of the U.S. government’s critical humanitarian aid mission.
As of December 31, 2023, the Company had approximately $104 million of cash and cash equivalents with approximately $279 million of total available liquidity, no outstanding borrowings on the Company’s $175 million credit facility, and a net leverage ratio of 0.2 times.
As of March 8, 2024, the Company repurchased approximately 1.9 million shares of its common stock for approximately $17.8 million. The stock repurchases, which commenced in January 2024, were executed pursuant to the $100 million stock repurchase program announced in November 2022 and represent approximately 17.8% of total share repurchase authorization executed to date. This repurchase program may be suspended from time to time, modified, extended or discontinued at certain times. Purchases under the repurchase program may be made from time to time in open market or privately negotiated transactions, and will be subject to market conditions, applicable legal requirements, contractual obligations and other factors. Any shares of common stock repurchased will be held as treasury shares.